Technical and economic benefits of membrane chromatography during polishing steps

BioPharm International

Volumn 23, Issue 8, 2010, Pages 44-52

  Fraud, Nathalie ^a   Lim, Janice ^b   Sinclair, Andrew ^b   Gottschalk, Uwe ^a  

^a SARTORIUS STEDIM BIOTECH GMBH   (Germany)

^b BioPharm Services UK   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

MONOCLONAL ANTIBODY; RESIN; STAINLESS STEEL;

ARTICLE; BIOMEDICAL TECHNOLOGY ASSESSMENT; CAPITAL; CELL CULTURE; COLUMN CHROMATOGRAPHY; CONTROLLED STUDY; DISPOSABLE EQUIPMENT; DRUG INDUSTRY; DRUG PURIFICATION; ENVIRONMENTAL FACTOR; FLOW RATE; INTERMETHOD COMPARISON; MURINE LEUKEMIA VIRUS; NONHUMAN; PROTEIN FOOTPRINTING; SEPARATION TECHNIQUE; VIRUS LOAD; WATER LOADING;

EID: 78650393883     PISSN: 1542166X     EISSN: None     Source Type: Trade Journal    
DOI: None     Document Type: Article

References (18)

1. Gottschalk U. Bioseparation in antibody manufacturing: the good, the bad, and the ugly. Biotechnol Prog. 2008;24:496-503.
2. Davis J. A purification platform for the production of mAbs from fermenters with titers of 5 g/L and beyond. BioPharm Int. 2009 Oct. Supplement:20-3.
3. Davis J. Economics of Monoclonal Antibody Production; the relationship between upstream title and downstream costs. IBC San Diego 2008.
4. Low D, O'Leary R, Pujar NS. Future of antibody purification. J Chromatogr B. 2007;848:48-63.
5. Schukla A, Hubbard B, Tressel T, Guhan S, Low D. Downstream processing of monoclonal antibodies-application of platform approaches. J Chromatogr B. 2007;848:28-39.
6. Thoemmes J, Etzel M. Alternatives to chromatographic separations. Biotechnol Prog. 2007;23:42-5.
7. Przybycien TM, Pujar NS, Steele LM. Alternative bioseparation operations: life beyond packed-bed chromatography. Curr Opin Biotechnol. 2004;15:469-78.
8. Fraud N. Membrane chromatography: an alternative to polishing column chromatography. Bioproc J. 2008;7:34-7.
9. Arunakumari A, Wang J, Ferreira G. Advances in non-Protein A purification processes for human monoclonal antibodies. BioPharm Int. 2009 Mar. Supplement: 22-6.
10. Gottschalk U, Fischer-Fruehholz S, Reif O. Membrane adsorbers, a cutting edge process technology at the threshold. BioProc Int. 2004;2:56-65.
11. DiBasi K, Jornitz M, Gottschalk U, Priebe PM. Disposable biopharmaceutical processes-myth or reality? BioPharm Int. Nov. 2006.
12. Lim JA, C, Sinclair A, Kim DS, Gottschalk U. Economic benefits of single-use membrane chromatography in polishing-a cost of goods model. BioProc Int. Feb. 2007;48-56.
13. Zhou JX, Tressel T. Basic concepts in Q membrane chromatography for large-scale antibody production. Biotechnol Prog. 2006;22:341-9.
14. Zhou JX, Tressel T, Gottschalk U, Solamo F, Pastor A, Dermawan S, Hong T, Reif O, Mora J, Hutchison F, Murphy M. New Q membrane scale-down model for process-scale antibody purification. J Chromatogr A. 2006;1134:66-73.
15. Zhou J, Tressel T, Guhan S. Disposable chromatography. Single-use membrane chromatography as a polishing option during antibody production is gaining momentum. Biopharm Int. 2007, Supplement Feb. 26-35.
16. Lim JAC, Sinclair A. Process economy of disposable manufacturing-process models to minimize upfront investment. Amer Pharmaceut Rev. 2007;10:114-21.
17. Sinclair A, Leveen L, Monge M, Lim J, Cox S. The Environmental Impact of Disposable Technologies. Can disposable technology reduce your facility's environmental footprint? BioPharm Int. 2008 Nov. Supplement:4-15.
18. Leveen L. Single-use technology and the carbon and water footprints of biopharm manuf. Amer Pharmaceut Rev. 2009 Sept/Oct;72-8.